Results 61 - 70 of 122
Researchers
| Name | Track | Location | View profile |
|---|---|---|---|
| Biomedical Engineering and Physiology | Minnesota | ||
IntroductionDr. Kenton Kaufman is a Consultant and Professor in Orthopedic Surgery with a joint appointment in Physiology and Biomedical Engineering. He directs the Motion Analysis Laboratory, where his multidisciplinary team advances biomechanics and motion analysis to develop objective measures of human movement that improve clinical decision-making and patient outcomes across orthopedics, rehabilitation, prosthetics, and related fields. Dr. Kaufman has been continuously funded by the National Institutes of Health, Department of Defense, and Veterans Administration for the past 35 years. His research efforts have resulted in over 325 peer-reviewed publications and 8 patents. He has mentored 6 Ph.D. students and trained 34 post-doctoral fellows. |
|||
| Biochemistry and Molecular Biology, Clinical and Translational Science | Minnesota | ||
Introduction
The primary mission of the Genetics of Liver Disease lab is to identify genetic drivers of liver disease and cancer and to discover new therapeutic targets. The lab uses CRISPR in vivo in the liver to identify genetic pathways involved in liver repopulation, homeostasis, and oncogenesis.
|
|||
| Biomedical Engineering and Physiology, Neuroscience | Minnesota | ||
IntroductionThe Smith-Edwards lab investigates the neural circuits of the gut-brain axis to understand how the nervous system and gastrointestinal tract communicate by integrating molecular, anatomical, functional, and behavioral approaches in preclinical models for human disease. Beyond our advanced technical approaches, my highest priority is building the next generation of independent scientists. I am deeply committed to cultivating a collaborative, inclusive, and supportive laboratory environment where trainees can push scientific boundaries, voice new ideas, and build the foundation for successful careers. We actively welcome motivated, inquisitive, and dedicated Ph.D. students. |
|||
| Biomedical Engineering and Physiology | Minnesota | ||
IntroductionI enjoy mentoring graduate students and postdoctoral fellows who are eager to develop as independent scientists and contribute to meaningful translational research. My work integrates biomechanics, rehabilitation, imaging, assistive technology, and clinical research to address complex problems with real patient impact. I aim to provide a collaborative and supportive mentorship environment that helps trainees strengthen scientific thinking, refine technical and communication skills, build a strong publication and funding trajectory, and grow into the next generation of research leaders. |
|||
| Biochemistry and Molecular Biology, Molecular Pharmacology and Experimental Therapeutics | Minnesota | ||
IntroductionDr. Dalvin is a surgeon-scientist with a clinical practice in ocular oncology and a translational research laboratory focused on uveal melanoma. Her laboratory pioneered the development of patient-derived organoid models for uveal melanoma, which provide a more translationally relevant platform for mechanistic and therapeutic studies. She has over 200 peer-reviewed publications and has held numerous leadership positions, including in ARVO, AAOOP, AAO, ISOO, and journal editorial boards. Her laboratory works toward better translation of novel therapeutics that will improve quality of life and overall survival for patients throughout the world affected by eye cancer. |
|||
| Biochemistry and Molecular Biology | Arizona | ||
Introduction
Dr. Bergsagel is a consultant and professor of medicine, co-leader of the Advanced Clinical Trials and Translational Science Research Program in the Mayo Clinic Comprehensive Cancer Center, and PI of the Mayo Clinic SPORE in Multiple Myeloma. He has been continuously funded by the NIH since 1997. He has successfully mentored multiple undergraduate, graduate and post-graduate students and authored over 300 publications. He identified recurrent immunoglobulin gene translocations as the molecular basis for myeloma initiation, recurrent MYC translocations as a molecular mechanism of myeloma progression, and developed a genetically engineered mouse model of multiple myeloma, Vk*MYC, based on sporadic activation of MYC in germinal center B-cells
|
|||
| Biomedical Engineering and Physiology, Immunology, Regenerative Science | Minnesota | ||
IntroductionDr. Griffith's laboratory has patented novel immunoproteomic methods for the identification of inciting causes (i.e., antigens) of immune-mediated response towards allograft (e.g., cardiac) and xenogeneic (e.g., heart valve) tissues and organs. The team leverages this information toward development of biomarker panels for allograft rejection and novel immunologically-acceptable extracellular matrix (ECM) scaffolds for cardiovascular regenerative medicine and tissue engineering. By combining such immunologically-acceptable ECM scaffolds with the patient’s own cells, the team aims to engineer new replacement tissues and organs which will be accepted as part of the patient's own body, providing immunosuppression-free lifelong function. |
|||
| Biomedical Engineering and Physiology, Immunology, Regenerative Science | Minnesota | ||
|
|
|||
| Biomedical Engineering and Physiology, Regenerative Science | Minnesota | ||
IntroductionDr. Lerman is involved in translational research, the development of animal models, and cardiovascular and renal imaging and therapeutic techniques. Her team focuses on the effects of cardiovascular risk factors on tissue injury and repair, senescence, and inflammation, including the effects of obesity, and is engaged in developing regenerative and cell-product-based (stem cells, extracellular vesicles, etc.) therapeutic approaches with applications in human subjects. Her laboratory is focused on a mission of teaching and possesses a vast mentorship experience, sustained by a host of pre- and post-doctoral trainees, who became successful investigators in renal and cardiovascular diseases. |
|||
| Biochemistry and Molecular Biology | Minnesota | ||
IntroductionMultiple myeloma (MM) and its precursor condition, MGUS, are nearly twice as common in individuals with high African genetic similarity, yet these patients often have lower rates of high-risk cytogenetic abnormalities and improved survival when access to care is comparable. We hypothesize that accelerated biological aging and immunosenescence of the bone marrow microenvironment increase disease risk while reducing tumor immunoediting. In collaboration with the Weivoda lab, we will assess biological aging using frailty measures, circulating senescence markers, and epigenetic clocks; characterize immune aging and T-cell fitness; and determine how immunosenescence shapes tumor evolution and immune selection in patient samples. |
|||